There are conflicting reports showing that alloxan or streptozotocin-induced diabetes in rat increases, decreases or does not alter blood pressure. Since hypertension influences organ-specific diabetic complications, this study was designed to examine the effects of streptozotocin-induced diabetes on blood pressure (BP), hemodynamics and heart weight in spontaneously hypertensive (SHR) and normotensive Wistar (NWR) rats. In order to control the influence of weight loss on BP affected by diabetes, we have examined the effect of weight loss without diabetes on BP, hemodynamics and heart weight in SHR. Weight loss parallel to that in diabetic SHR was induced in a group of SHR by food restriction (fasting). Significant (P less than .05) decreases in systolic and direct BP were observed in diabetic SHR. This hypotensive effect was accompanied by a significant (P less than .05) decrease in total peripheral resistance, but no change in cardiac output. These blood pressure and hemodynamic findings in diabetic SHR were complimented by a significant (P less than .05) reduction in left ventricular weight to body weight ratio. On the contrary, fasting SHR with weight loss equivalent to that in diabetic SHR showed no change in BP or total peripheral resistance. Further, fasting SHR revealed a significant (P less than .05) increase in heart weight to body weight ratio. The weight loss of equal magnitude induced by streptozotocin-induced diabetes in NWR did not have any effect on BP or hemodynamics. In addition, like fasting SHR, diabetic NWR showed a significant (P less than .05) increase in left ventricular weight to body weight ratio.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/10641969009073515 | DOI Listing |
Background: Long-term recurrent weight gain remains a persistent challenge in metabolic bariatric surgery (MBS). One strategy for managing recurrent weight gain involves the placement of a non-adjustable silicone ring around the reduced stomach pouch. This technique may lead to more significant weight loss and a reduced risk of long-term recurrent weight gain.
View Article and Find Full Text PDFObes Surg
March 2025
Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Background: Roux-en-Y gastric bypass (RYGB) is widely regarded as a cornerstone intervention for individuals afflicted with metabolic syndromes and severe obesity. However, one anastomosis gastric bypass (OAGB) emerged after RYGB as a more straightforward and less technically demanding operation. This systematic review and meta-analysis aims to compare both procedures and update the currently existing evidence.
View Article and Find Full Text PDFObes Surg
March 2025
Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Background: Metabolic and bariatric surgery is an effective intervention for severe obesity, known for improving comorbidities such as type 2 diabetes, hypertension, and hyperlipidemia. However, its association with kidney stone formation remains uncertain. This study investigates the relationship between bariatric surgery and kidney stone prevalence using data from NHANES 2015-2018.
View Article and Find Full Text PDFClin J Am Soc Nephrol
March 2025
Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.
Obesity is a worldwide epidemic with a future projected growth of 40% over ten years. Obesity increases the risk of diabetes, hypertension and cardiovascular disease, and it also leads to higher risk of chronic kidney disease, both through direct and indirect mechanisms. While obesity is a feature of over-nutrition and is associated with poor outcomes in the general population, obese individuals with chronic kidney disease often display complex metabolic patterns such as sarcopenic obesity, and obesity can be associated with better survival in individuals with advanced chronic kidney disease.
View Article and Find Full Text PDFJAMA Health Forum
March 2025
Department of Medicine, University of Chicago, Chicago, Illinois.
Importance: Newer antiobesity medications lead to greater weight loss and lower cardiometabolic risks. However, the high costs of these medications have raised policy questions about their value and coverage decisions.
Objective: To compare the cost-effectiveness of 4 antiobesity medications with lifestyle modification vs lifestyle modification alone in the US.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.